GlassScriptPhysician profile
Priya J Mathur
NPI 1124763669
$12,104.57
in general payments reported to CMS, 2019-2025
65 companies · $3,861 in 2025
The $3,861 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,521 · 2023: $2,835 · 2024: $3,887 · 2025: $3,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,478 · Long Term Medical Supply Or Device Loan: $1,379 · Education: $446 · Consulting Fee: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,478.18 |
| Long Term Medical Supply Or Device Loan | $1,379.43 |
| Education | $445.88 |
| Consulting Fee | $280.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,141.31 | 2022-2025 | |
| Janssen Biotech, INC. | $947.95 | 2022-2025 | Erleada, Rybrevant, Imbruvica |
| Abbvie INC. | $727.55 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $604.95 | 2022-2025 | Lynparza, Enhertu, Calquence |
| Incyte Corporation | $507.67 | 2022-2025 | Jakafi, Niktimvo, Pemazyre |
| Taiho Oncology, INC. | $461.27 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $381.34 | 2022-2025 | Monoferric, Cosela |
| Genentech USA, INC. | $372.44 | 2022-2025 | Tecentriq, Venclexta, Polivy |
| Daiichi Sankyo INC. | $341.60 | 2022-2025 | Enhertu, Injectafer |
| Lilly USA, LLC | $314.33 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $308.07 | 2022-2025 | Ninlaro, Alunbrig, Iclusig |
| Sobi, INC | $270.68 | 2022-2025 | |
| Adaptive Biotechnologies Corporation | $268.29 | 2023-2025 | Clonoseq |
| Merck Sharp & Dohme LLC | $251.82 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Regeneron Healthcare Solutions, INC. | $245.24 | 2022-2025 | Libtayo |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $237.20 | 2022-2025 | |
| Astellas Pharma US INC | $215.30 | 2022-2025 | Padcev, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $185.32 | 2022-2025 | Reblozyl, Opdivo |
| Array Biopharma INC | $184.52 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Glaxosmithkline, LLC. | $170.22 | 2022-2025 | Ojjaara |
| Amgen INC. | $167.41 | 2022-2023 | Kyprolis, Vectibix, Nplate |
| Celgene Corporation | $164.89 | 2023-2025 | Reblozyl, Opdualag |
| Stemline Therapeutics INC. | $163.94 | 2023-2025 | Orserdu, Elzonris |
| Eisai INC. | $151.92 | 2022-2024 | |
| Servier Pharmaceuticals LLC | $136.51 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $123.91 | 2022-2025 | Xpovio |
| Acrotech Biopharma INC. | $116.21 | 2022-2025 | Beleodaq |
| Puma Biotechnology, INC. | $106.19 | 2022-2025 | |
| Cti Biopharma Corp. | $103.58 | 2022-2023 | Vonjo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.58 | 2023-2025 | Gilotrif |
| Aveo Pharmaceuticals, INC. | $95.67 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $95.58 | 2022-2024 | Ultomiris |
| Tersera Therapeutics LLC | $90.83 | 2025 | Quzyttir, Xermelo |
| Genmab U.S., INC. | $79.78 | 2023-2025 | Epkinly, Tivdak |
| G1 Therapeutics, INC. | $78.82 | 2022-2023 | Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $76.66 | 2022-2025 | |
| Kyowa Kirin, INC. | $70.51 | 2023-2025 | Poteligeo |
| Geron Corporation | $66.75 | 2025 | Rytelo |
| Exelixis INC. | $66.67 | 2022-2024 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $62.54 | 2023 | Imbruvica |
| Sandoz INC. | $56.86 | 2024-2025 | Cyclophosphamide |
| Seagen INC. | $55.38 | 2022-2023 | Padcev, Tukysa |
| Genzyme Corporation | $54.69 | 2022-2025 | |
| Adc Therapeutics America, INC. | $52.66 | 2022-2025 | |
| Eusa Pharma (US) LLC | $52.48 | 2022 | |
| Legend Biotech USA INC. | $47.99 | 2025 | Carvykti |
| Rigel Pharmaceuticals, INC. | $45.70 | 2025 | Tavalisse |
| Deciphera Pharmaceuticals INC. | $41.99 | 2023-2024 | Qinlock |
| Pharmaessentia USA Corporation | $40.41 | 2024 | Besremi |
| Csl Behring | $37.22 | 2024 | Hemgenix |
| Celltrion USA INC. | $36.57 | 2024 | Vegzelma |
| Sun Pharmaceutical Industries INC. | $35.78 | 2022-2024 | |
| Beigene USA, INC. | $32.91 | 2023 | Brukinsa |
| Azurity Pharmaceuticals, INC. | $30.88 | 2025 | Danziten |
| Beone Medicines USA, INC. | $28.28 | 2025 | Brukinsa |
| Cycle Pharmaceuticals INC | $26.39 | 2025 | Phyrago |
| Myriad Genetic Laboratories, INC. | $26.33 | 2022-2024 | Myrisk |
| Gilead Sciences, INC. | $23.28 | 2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $22.89 | 2023 | |
| Emd Serono, INC. | $20.58 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $18.45 | 2023 | Onivyde, Somatuline Depot |
| Amneal Pharmaceuticals LLC | $18.35 | 2025 | Alymsys |
| Secura Bio, INC. | $16.44 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $16.39 | 2022 | |
| Coherus Oncology, INC. | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.